A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma
2022
Frontiers in Immunology
BackgroundLocally advanced rectal cancers (LARC) show a highly variable response to neoadjuvant chemoradiotherapy (nCRT), and the impact of the tumor immune response in this process is poorly understood. This study aimed to characterize the immune-related gene expression profiles (GEP), pathways, and cell types associated with response or resistance to neoadjuvant chemoradiotherapy.MethodsThe transcriptomic and clinical data of Rectal carcinoma from the Gene Expression Omnibus database and
doi:10.3389/fimmu.2022.784479
pmid:35603163
pmcid:PMC9121132
fatcat:rl7mbbcwlbfi3h3mhvdrsxlf7q